rezatomidine

Rezatomidine (AGN 203818) is an investigational small molecule drug developed by Allergan for the treatment of pain associated with fibromyalgia syndrome and irritable bowel syndrome. It was evaluated in multiple phase 2 clinical trials to assess its safety and efficacy for these indications. The precise mechanism of action has not been publicly disclosed, but it is presumed to act as a centrally acting analgesic or neuromodulator based on its development focus. Rezatomidine is not approved for any indication, and clinical development appears to have been discontinued following terminated phase 2 studies.

Brand names

rezatomidine

Other names

rezatomidineAGN-203818 hydrochlorideAGN203818 hydrochlorideAGN 203818 hydrochlorideREZATOMIDINE HYDROCHLORIDE